Changes in Hepatic Fibrosis and Incidence of HCC Following Direct-Acting Antiviral Treatment of F3 Chronic Hepatitis C Patients: A Prospective Observational Study

Recommended

Association of Geriatric Measures and Global Frailty With Cognitive Decline After Allogeneic Hematopoietic Cell Transplantation in Older Adults

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Changes in Hepatic Fibrosis and Incidence of HCC Following Direct-Acting Antiviral Treatment of F3 Chronic Hepatitis C Patients: A Prospective Observational Study

header-info

Nov, 22, 2022

Chronic hepatitis C patients with F3 fibrosis showed a high rate of regression of fibrosis and decreased HCC incidence after achieving sustained virologic response following direct acting antivirals.